nervous system autoimmune diseases
Conditions
Interventions
MS patients:none
Patients with neuromyelitis optica spectrum disease and other central demyelinating diseases:none
healthy control:none
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: MS Patient Group 1. Chinese citizens of both sexes aged 14 to 65 years old; 2. The diagnosis of multiple sclerosis (MS) should be made in the neuroimmunology specialist clinic of Huashan Hospital. Two or more experienced specialists are recommended to make the diagnosis of MS independently, excluding other possible diseases; 3. The diagnostic criteria referred to the 2010 McDonald standard; 4. Agree receiving venous blood collection and follow-up; 5. Understand and sign informed consent; Control group 1 (patients with other central demyelinating disorders such as neuromyelitis optica spectrum disorders) 1. Chinese citizens of both sexes aged 14 to 65 years old; 2. The diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and other central demyelinating diseases should be performed in the neuroimmunology specialist clinic of Huashan Hospital. Two or more experienced specialists are recommended to make the diagnosis of NMOSD independently, excluding other possible diseases; 3. The diagnostic criteria of neuromyelitis optica spectrum disorders (NMOSD) refer to the Chinese Guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders (2021 edition); 4. The diagnostic criteria of MOG-IgG related disorders (MOGAD) refer to the Chinese expert consensus on the diagnosis and treatment of MOGAD (2020 version); 5. Understand and sign informed consent; 6. Agree receiving venous blood collection and follow-up. Control group 2 (healthy people) 1. Chinese citizens of both sexes aged 14 to 65 years old; 2. No history of hospitalization in the past 6 months; 3. Understand and sign informed consent; 4. Able to cooperate with the completion of venous blood collection and follow-up.
Exclusion criteria
Exclusion criteria: MS Patient Group 1. Patients with pregnancy; 2. Have joined other clinical investigators in the past 3 months; 3. Patients whose diagnosis of multiple sclerosis (MS) is not considered by two or more experts; 4. AQP4-IgG, MOG-IgG and other known demyelinating disease-related antibodies positive; 5. Patients who have contraindications to blood collection or cannot accept blood collection; 6. Patients with definite infection (including latent infection) and malignant tumors; 7. History of mental illness or substance abuse; 8. Other conditions deemed ineligible for inclusion by the investigators. Control group 1 (patients with other central demyelinating disorders such as neuromyelitis optica spectrum disorders) 1. Patients with pregnancy; 2. Have joined other clinical investigators in the past 3 months; 3. Patients who have contraindications to blood collection or cannot accept blood collection; 4. Patients with definite infection (including latent infection) and malignant tumors; 5. History of mental illness or substance abuse; 6. Other conditions considered by the investigators to be ineligible for inclusion. Control group 2 (healthy people) 1. Patients with pregnancy; 2. Have joined other clinical investigators in the past 3 months; 3. Patients who have contraindications to blood collection or cannot accept blood collection; 4. Patients with definite infection (including latent infection) and malignant tumors; 5. History of mental illness or substance abuse; 6. Other conditions considered by the investigators to be ineligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heat shock protein 90; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokines like interleukin-1, interleukin-6, tumor necrosis factor-a, etc.;The distribution of immune cell subsets (such as Th1, Th2, Th17, Treg cells); | — |
Countries
China
Contacts
Public ContactChen Xiangjun
Huashan Hospital, Fudan University
Outcome results
None listed